Gene therapy strategies for RAG1 deficiency: Challenges and breakthroughs

Immunol Lett. 2024 Dec:270:106931. doi: 10.1016/j.imlet.2024.106931. Epub 2024 Sep 18.

Abstract

Mutations in the recombination activating genes (RAG) cause various forms of immune deficiency. Hematopoietic stem cell transplantation (HSCT) is the only cure for patients with severe manifestations of RAG deficiency; however, outcomes are suboptimal with mismatched donors. Gene therapy aims to correct autologous hematopoietic stem and progenitor cells (HSPC) and is emerging as an alternative to allogeneic HSCT. Gene therapy based on viral gene addition exploits viral vectors to add a correct copy of a mutated gene into the genome of HSPCs. Only recently, after a prolonged phase of development, viral gene addition has been approved for clinical testing in RAG1-SCID patients. In the meantime, a new technology, CRISPR/Cas9, has made its debut to compete with viral gene addition. Gene editing based on CRISPR/Cas9 allows to perform targeted genomic integrations of a correct copy of a mutated gene, circumventing the risk of virus-mediated insertional mutagenesis. In this review, we present the biology of the RAG genes, the challenges faced during the development of viral gene addition for RAG1-SCID, and the current status of gene therapy for RAG1 deficiency. In particular, we highlight the latest advances and challenges in CRISPR/Cas9 gene editing and their potential for the future of gene therapy.

Keywords: CRISPR/Cas9; Gene editing; Gene therapy; RAG deficiency; RAG1; Viral gene addition.

Publication types

  • Review

MeSH terms

  • Animals
  • CRISPR-Cas Systems*
  • Gene Editing*
  • Genetic Therapy* / methods
  • Genetic Vectors / genetics
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells / metabolism
  • Homeodomain Proteins / genetics
  • Humans
  • Mutation
  • Severe Combined Immunodeficiency / genetics
  • Severe Combined Immunodeficiency / therapy

Substances

  • RAG-1 protein
  • Homeodomain Proteins